CTOs on the Move

G and W Laboratories

www.gwlabs.com

 
Carl Greenblatt founded G&W Laboratories, Inc. in 1919 upon his return from military service as a pharmacist with US forces in World War I. While establishing a reputation as an innovative specialist in suppository dosage forms, Carl guided G&W Laboratories with an uncompromising commitment to product integrity and customer service. In 1945, Carl’s son, Burton, also a registered pharmacist, returned from military service in World War II and joined the small but growing company. During the post-war years, G&W expanded its product line beyond suppositories, into creams, ointments, gels and liquids. G&W moved to a larger state-of-the-art laboratory and production ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.gwlabs.com
  • 111 Coolidge St
    South Plainfield, NJ USA '07080
  • Phone: 908.753.2000

Executives

Name Title Contact Details

Similar Companies

Tahiti Trade Super Nutaceuticals

Tahiti Trade Super Nutaceuticals is a Riverside, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HealthChem Contract Services

HealthChem Contract Services is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MnPharm

MNPHARM SBC is a manufacturer of recombinant regenerative proteins using a proprietary method called molecular farming. We supply these proteins to researchers working on therapeutic development. Our plant based expression method only takes 6 to 8 days. We offer faster production and lower cost resulting in rapid therapeutic development.

Clinical DataFax Systems

Clinical DataFax Systems, Inc. is a Hamilton, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ascentage Pharma

Ascentage Pharma is a globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases. Based on breakthrough technology from the University of Michigan, the Company`s expertise is in designing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death, in cancers. Ascentage has built a rich pipeline of six clinical candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, APG-1252, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors.